SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Allogeneic, BCMA, CAR-T, CD19

May 05, 2023

ALLO-501’s ALPHA2 Trial Progresses but EXPAND Study Might Experience Difficulties to Enroll; ALLO-316’s AACR Results Highlighted; Allogene Ready for Partnerships to Advance its Programs; Allogene’s Q1 2023 Earnings Call Summary

Here is a brief preview of this blast: On Wednesday, May 3, Allogene held its Q1 2023 earnings call (press release / presentation) highlighting the progress made in ALLO-501A’s (allogeneic CD19 CAR-T) ALPHA2 trial while admitting that some clinical trial sites have declined to participate in the EXPAND trial due to its randomized design. Below, Celltelligence provides insights on the consequences of Allogene’s decision to include ALLO-647 (anti-CD52 mAb) in its lymphodepletion regimen for the administration of ALLO-501A and its other cell therapies while discussing potential plans to partner for the development of any of its cell therapy programs.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.